Mohamed Fares Mahmoud Mohamed Metwaly

Mr. Mohamed Fares Mahmoud Mohamed Metwaly


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2015 in Molecules
Verified
Journal Article
Open access
PDF file
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
MAMarwa Abdel-Aziz
Marwa Abdel-Aziz
HAHatem Abdel-Aziz
Hatem Abdel-Aziz
Three series of 6-aryl-2-methylnicotinohydrazides 4a–i, N′-arylidene-6-(4-bromophenyl)-2-methylnicotino hydrazides 7a–f, and N′-(un/substituted 2-oxoindolin-3-ylidene)-6-(4-fluorophenyl)-2-methylnicotinohydrazides 8a–c were synthesized and evaluated for their potential in vitro antimycobacterial activity against M. tuberculosis. The results showed that isatin hydrazides 8a–c are remarkably more active than the parent hydrazide 4c. Hydrazides 8b and 8c exhibited the highest activity among all the tested compounds (MIC = 12.5 and 6.25 µg/mL, respectively). Compounds 8b and 8c were also devoid of apparent cytotoxicity to HT-29, PC-3, A549, HepG2 and MCF-7 cancer cell lines. Besides, 8b and 8c showed good drug-likeness scores of 0.62 and 0.41, respectively. Those two isatin hydrazides could offer an excellent framework for future development to obtain more potent antitubercular agents. The SAR study suggested that lipophilicity of the synthesized derivatives is a crucial element that accounts for their antimycobacterial activity. Finally, a theoretical kinetic study was established to predict the ADME of the active derivatives.

1 January 2019 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
Maz AliMaz Ali
Maz Ali
WAWessam H. Abd-Elsalam
Wessam H. Abd-Elsalam
SBShymaa A. El Badawy
Shymaa A. El Badawy
ETEhab Taher
Ehab Taher
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
CLChun Guang Li
Chun Guang Li

12 June 2018 in Molecules
Verified
Journal Article
Open access
PDF file
MNMohamed El Naggar
Mohamed El Naggar
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
Hadia AlmahliHadia Almahli
Hadia Almahli
AEAmr Elgez
Amr Elgez
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
HAHatem Abdel-Aziz
Hatem Abdel-Aziz
In connection with our research program on the development of new isatin-based anticancer candidates, herein we report the synthesis of two novel series of thiazolidinone-isatin conjugates (4a–n) and thiazolo[3,2-a]benzimidazolone-isatin conjugates (7a–d), and in vitro evaluation of their antiproliferative activity towards two breast cancer cell lines; triple negative MDA-MB-231, and MCF-7. Compounds 4m and 7b emerged as the most active congeners against MDA-MB-231 cells (IC50 = 7.6 ± 0.5 and 13.2 ± 1.1 µM, respectively). Compounds 4m and 7b were able to provoke apoptosis in MDA-MB-231 cells, evidenced by the up-regulation of Bax and down-regulation of Bcl-2, besides boosting caspase-3 levels. Hybrid 4m induced a fourfold increase in the percentage of cells at Sub-G1, with concurrent arrest in G2-M phase by 2.5-folds. Furthermore, hybrid 4m resulted in a sixfold increase in the percentage of annexin V-FITC positive apoptotic MDA-MB-231 cells as compared with the control. Moreover, the cytotoxic activities of the active conjugates were assessed towards two nontumorigenic cell lines (breast MCF-10A and lung WI-38) where both conjugates 4m and 7b displayed mean tumor selectivity index: 9.6 and 13.9, respectively. Finally, several ADME descriptors were predicted for the active conjugates via a theoretical kinetic study.

24 June 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
Xin WuXin Wu
Xin Wu
DRDeepthi Ramesh
Deepthi Ramesh
WLWilliam Lewis
William Lewis
PKPaul Keller
Paul Keller
Philip GalePhilip Gale
Philip Gale

7 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
SBSilvia Bua
Silvia Bua
CLCecilia Lanzi
Cecilia Lanzi
LLLaura Lucarini
Laura Lucarini
Claudiu SupuranClaudiu Supuran
Claudiu Supuran

1 April 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MMMohamed Fares Mahmoud Mohamed Metwaly
Mohamed Fares Mahmoud Mohamed Metwaly
RERadwa A. Eladwy
Radwa A. Eladwy
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
SHSoha R. Abd El Hadi
Soha R. Abd El Hadi
HGHazem A. Ghabbour
Hazem A. Ghabbour
Claudiu SupuranClaudiu Supuran
Claudiu Supuran